The Recall Desk
ModerateFDA (Devices)·Z-0663-2020·Announced 2019-12-18

LivaNova VNS Therapy Tablet Software Recall for Diagnostic Error

LivaNova is recalling 643 VNS Therapy Program tablets due to a software error that causes incorrect diagnostic tests on specific devices.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves a software error leading to incorrect diagnostic data (false high impedance values) rather than a direct physical injury or death.

Plain-English summary

LivaNova USA Inc is recalling 643 units of the VNS Therapy Program (GMDN: 44077, Model # 3000, Version 1.5.2). The recall is initiated due to reports that the therapy programming tablet with software version 1.5 errantly performs a normal mode diagnostic test instead of the selected system diagnostic test on Model 102 and Model 102R devices when the output current is greater than 0.5mA.

This software error can result in false high impedance values during patient follow-up. The affected units were distributed across numerous states, including Illinois, Alaska, Alabama, Arkansas, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Iowa, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Maryland, Michigan, Minnesota, Missouri, Mississippi, Montana, North Carolina, North Dakota, Nebraska, New Jersey, New Mexico, Nevada, New York, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin, West Virginia, and Wyoming.

Patients using the affected VNS Therapy Program tablets should contact their healthcare provider or LivaNova for further instructions regarding the diagnostic error.

The recalled product

Product
VNS Therapy Program GMDN: 44077 Model # 3000 V1.5.2, RxOnly
Manufacturer
LivaNova USA Inc
Affected units
643

Distribution